J. Safra Sarasin Holding’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Safra Sarasin Holding’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02M	Hold	4,195	–	–	0.03%	263
2026 Q1	$1.87M	Buy	4,195 +1,195	+40%	+$557K	0.03%	217
2025 Q4	$1.36M	Sell	3,000 -827	-22%	-$356K	0.02%	242
2025 Q3	$1.5M	Buy	3,827 +827	+28%	+$346K	0.02%	241
2025 Q2	$1.34M	Sell	3,000 -946	-24%	-$436K	0.02%	276
2025 Q1	$1.91M	Sell	3,946 -51,950	-93%	-$24.2M	0.03%	227
2024 Q4	$22.5M	Sell	55,896 -4,246	-7%	-$1.97M	0.38%	71
2024 Q3	$28M	Sell	60,142 -7,478	-11%	-$3.59M	0.49%	64
2024 Q2	$31.7M	Buy	+67,620	New	+$29.4M	0.58%	50

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

J. Safra Sarasin Holding's VRTX Position: Q2 2026 in Review

J. Safra Sarasin Holding held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4,195 shares worth $2.02M. The position accounts for 0.03% of the portfolio, ranked #263.

J. Safra Sarasin Holding first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $31.7M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

J. Safra Sarasin Holding held 4,195 shares of Vertex Pharmaceuticals worth $2.02M as of Q2 2026.
J. Safra Sarasin Holding left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.03% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #263 holding.
J. Safra Sarasin Holding first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
J. Safra Sarasin Holding's Vertex Pharmaceuticals position peaked at $31.7M in Q2 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.